TICKERNERD
Menu
HCAHCAHealthcare · Medical Care Facilities

HCA Stock Forecast: HCA Healthcare, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$407
+1.00% on the day

The 25 Wall Street analysts covering HCA Healthcare, Inc. hold a median 12-month price target of $450 — +10.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$87.2B
Ticker Nerd rank
66 / 100
Median analyst target
$450
Analysts covering
25
Total return, dividends reinvested
1W
+4.4%
1M
−0.9%
YTD
−12.6%
1Y
+14.7%
From 52W high
−25.1%
From 52W low
+12.8%
$361
$543
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HCA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HCA Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Value
90
Volatility
88
Growth
76
Issuance
60
Accruals
50
Momentum
49
Revisions
38
Size
3

Quality (91): The business earns solid, repeatable profits on what it owns.

Revisions (38): Analysts have, on balance, been cutting their forecasts.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own HCA Healthcare, Inc. — and when they’d sell — is the membership.

Wall Street

HCA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HCA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$350$400$450$500$550$600Oct 25Jan 26Apr 26Jul 26HCAHigh $579Median $450Low $380

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says25 analysts
14 Buy10 Hold1 Sell
Low $380Median $450High $579

The green dot is the last close — the median target sits +10.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 14 moved it down.

DateFirmActionRatingTarget
3 Aug 2026Wells FargoMaintainsEqual-Weight$369 → $381
28 July 2026Goldman SachsMaintainsBuy$558 → $485
28 July 2026MizuhoMaintainsOutperform$525 → $475
27 July 2026BairdMaintainsNeutral$396 → $393
27 July 2026BarclaysMaintainsEqual-Weight$402 → $387
27 July 2026KeybancMaintainsOverweight$475 → $435
27 July 2026Morgan StanleyMaintainsUnderweight$425 → $380
27 July 2026OppenheimerMaintainsOutperform$520 → $485
27 July 2026RBC CapitalReiteratesOutperform$435
27 July 2026Truist SecuritiesMaintainsBuy$535 → $495
27 July 2026UBSMaintainsBuy$635 → $579
16 July 2026BarclaysMaintainsEqual-Weight$427 → $402
16 July 2026BarclaysMaintainsEqual-Weight—
15 July 2026RBC CapitalMaintainsOutperform—
15 July 2026RBC CapitalMaintainsOutperform$534 → $435
14 July 2026KeybancMaintainsOverweight$510 → $475
14 July 2026KeybancMaintainsOverweight—
13 July 2026Wells FargoMaintainsEqual-Weight$436 → $428
13 July 2026Wells FargoMaintainsEqual-Weight—
8 July 2026BarclaysDowngradeEqual-Weight$496 → $427

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

HCA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

HCA Healthcare, Inc. (HCA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.6×

Cheaper than 50% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
−27.6×

Cheaper than 98% of US stocks

EV / EBITDA
9.0×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
8.7%

Higher than 51% of US stocks

Earnings growth (YoY)
2.8%

Higher than 40% of US stocks

Gross margin
44.8%

Higher than 57% of US stocks

Operating margin
15.2%

Higher than 74% of US stocks

Net margin
8.8%

Higher than 67% of US stocks

Returns & dividend
Return on equity
−244.8%

Higher than 5% of US stocks

Return on assets
12.3%

Higher than 95% of US stocks

Dividend yield
0.8%

Higher than 16% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HCA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
HCAHCA Healthcare, Inc.$87.2B
66
THCTenet Healthcare Corp.$20.5B
96
DVADaVita, Inc.$16.0B
96
EHCEncompass Health Corp.$11.0B
75
UHSUniversal Health Services, Inc.$10.5B
64
ENSGThe Ensign Group, Inc.$10.3B
69
PACSPACS Group, Inc.$7.1B
91
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest HCA news & analysis

HCA SHAREHOLDER ALERT: HCA Healthcare, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Business Wire · 4 Aug 2026negative

Kirby McInerney LLP announced an investigation on behalf of HCA Healthcare, Inc. investors into possible violations of federal securities laws or other unlawful business practices by the Company and/or its senior management. The alert references a July 14, 2026 press release in which HCA reported preliminary financial and operational results.

Why it matters — A securities-law investigation into HCA and its leadership introduces potential legal and regulatory risk for the company and its shareholders.

First Eagle U.S. Fund Q2 2026 Portfolio Review

Seeking Alpha · 28 July 2026negative

In its Q2 2026 portfolio review, First Eagle U.S. Fund reported HCA Healthcare as one of the leading detractors during the quarter.

Why it matters — HCA being named a top detractor in a major fund's quarterly review signals the stock underperformed relative to the fund's other holdings in the period.

HCA Healthcare Analysts Slash Their Forecasts After Q2 Results

Benzinga · 27 July 2026negative

HCA Healthcare reported better-than-expected second-quarter earnings, but analysts subsequently lowered their forecasts for the company.

Why it matters — The reduction in analyst forecasts following the earnings report signals potential concern about HCA's future performance despite the quarterly beat.

HCA Healthcare, Inc. (HCA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 24 July 2026neutral

HCA Healthcare released the transcript of its Q2 2026 earnings call on Seeking Alpha, covering the company's financial results and management commentary for the quarter.

Why it matters — Earnings call transcripts provide HCA watchers with direct insight into management's perspective on the company's quarterly performance and outlook.

HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised

Zacks Investment Research · 24 July 2026neutral

HCA reported second-quarter earnings that beat analyst estimates, driven by higher admissions and revenue per admission. However, the company trimmed parts of its 2026 guidance due to higher expenses and weaker surgical volumes.

Why it matters — The mixed results show HCA benefiting from strong patient volumes while facing cost pressures that could affect its longer-term financial trajectory.

FAQ

Frequently asked questions about HCA stock

What is the HCA stock price forecast for 2026-2027?

The 25 Wall Street analysts covering HCA Healthcare, Inc. have a median 12-month price target of $450, with estimates ranging from $380 to $579. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HCA stock a buy right now?

Of the 25 analysts covering HCA Healthcare, Inc., 14 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks HCA Healthcare, Inc. 66 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HCA?

As at 1 Aug 2026, HCA Healthcare, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will HCA stock go up?

No one can know that. What the data says: the median 12-month target from 25 analysts implies +10.7% from the last close, and Ticker Nerd's factor model ranks HCA Healthcare, Inc. 66 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HCA stock forecast for 2030?

No analyst covering HCA Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $380 to $579 over the next 12 months.

How has HCA stock performed over the past year?

HCA Healthcare, Inc. returned +14.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HCA Healthcare, Inc. do?

HCA Healthcare Inc. is a healthcare services company that operates hospitals, freestanding surgery centers, emergency care facilities, urgent care clinics, walk-in clinics, diagnostic and imaging centers, rehabilitation centers, physician practices, home health, hospice, and outpatient therapy services.

What is the latest news on HCA?

The most recent item we track (Business Wire, 4 Aug 2026): "HCA SHAREHOLDER ALERT: HCA Healthcare, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations". Kirby McInerney LLP announced an investigation on behalf of HCA Healthcare, Inc. investors into possible violations of federal securities laws or other unlawful business practices by the Company and/or its senior management. The alert references a July 14, 2026 press release in which HCA reported preliminary financial and operational results.

Company

About HCA Healthcare, Inc.

HCA Healthcare Inc. is a healthcare services company that operates hospitals, freestanding surgery centers, emergency care facilities, urgent care clinics, walk-in clinics, diagnostic and imaging centers, rehabilitation centers, physician practices, home health, hospice, and outpatient therapy services. It serves patients through a broad network of acute care hospitals and ambulatory sites across the United States and the United Kingdom. The company focuses on delivering inpatient and outpatient care, including medical and surgical services, emergency treatment, cardiac care, radiology, laboratory services, and physical therapy. HCA Healthcare Inc. plays a central role in organized healthcare delivery by connecting hospital-based care with community-based and specialty services, supporting access to a wide range of clinical offerings across multiple care settings.

CEO Mr. Samuel N. Hazen · 230,000 employees · United States · https://www.hcahealthcare.com